Haisco Pharmaceuticals Co., Ltd
While maintaining a similar or slightly better safety and efficacy profilecomparing to propofol, HSK3486 hasdemonstrated promising improvements over propofol in reducing pain on injection and lipid intake in multiple Phase 1 & 2 clinical studies conducted to date. As HSK3486 is about 5-fold more potent than propofol, merely 1/5 of the dose is required to achieve similar anesthesia effect. Besides reducing pain on injection, the 5-fold dose reduction will contribute in clinically meaningful reduction in lipid intake in ICU sedation. These improvements are expected to translate into meaningful patient and market acceptance of HSK3486 over propofol.